Sanofi Pasteur Announces FDA Approval Of Menactra Meningococcal Conjugate Vaccine Indication For Infants

04/26/11 Sanofi Pasteur, the vaccines division of the sanofi-aventis Group (EURONEXT: SAN and NYSE: SNY), announced today that the U.S. Food and Drug Administration (FDA) has granted licensure to expand the indication for its meningococcal conjugate vaccine, Menactra® (Meningococcal [Groups A, C, Y and W-135] Polysaccharide Diphtheria Toxoid Conjugate Vaccine), to include a two-dose schedule for infants ...

+

-

 

Sanofi Pasteur, EnGen Bio and Dyadic Nederland sign research deal for vaccine development

05/02/11 Dyadic International, Inc., a global biotechnology company focused on the discovery, development, manufacture and sale of enzyme and protein products for the biopharmaceutical, biofuels and industrial enzyme industries, announced today that its research and development subsidiary, Dyadic Nederland B.V., has entered into a research agreement with Sanofi Pasteur, the vaccines division of sanofi ...

+

-

 

Factors Affecting Vaccine Production, Access, And Uptake: Are We Ready For Another Flu Pandemic?

06/09/11 In the third paper of the Series, Professor Jeffrey W Almond and Dr Jon Smith, Sanofi Pasteur, Marcy L'Etoile, France, and Professor Marc Lipsitch, Harvard School of Public Health, Boston, MA, USA, look at the range of factors that influencing vaccine production, access, and uptake, and focus on the H1N1 influenza pandemic to exemplify the challenges of vaccine development on a global scale. The ...

+

-